A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin
Latest Information Update: 27 Mar 2023
At a glance
- Drugs Citatuzumab bogatox (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sesen Bio; Viventia Biotechnologies
- 09 Apr 2008 Status changed from recruiting to discontinued, as reported in ClinicalTrials.gov.
- 25 Jun 2007 New trial record.